NCT02763254View on ClinicalTrials.gov

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

February 17, 2018

Study Completion Date

February 17, 2018

Conditions

Hodgkin LymphomaLymphoma, Large B-Cell, DiffusePost-transplant Lymphoproliferative Disorder

Interventions

BIOLOGICAL

baltaleucel-T

Autologous EBV-specific T cells

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Cell Medica Ltd

All Listed Sponsors

lead

Cell Medica Ltd

INDUSTRY

NCT02763254 - Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas | Biotech Hunter | Biotech Hunter